21.04 USD
-2.38 (-10.16%)
Taking everything into account, LEGN scores 4 out of 10 in our fundamental rating. LEGN was compared to 525 industry peers in the Biotechnology industry. LEGN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. LEGN shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
- LEGN had negative earnings in the past year.
- In the past year LEGN has reported a negative cash flow from operations.
- LEGN had negative earnings in each of the past 5 years.
- In the past 5 years LEGN always reported negative operating cash flow.
1.2 Ratios
- Looking at the Return On Assets, with a value of -14.01%, LEGN belongs to the top of the industry, outperforming 80.57% of the companies in the same industry.
- LEGN's Return On Equity of -23.73% is amongst the best of the industry. LEGN outperforms 80.57% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -14.01% | ||
| ROE | -23.73% | ||
| ROIC | N/A |
ROA(3y)-24.06%
ROA(5y)-29.02%
ROE(3y)-39.46%
ROE(5y)-43.13%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- With a decent Gross Margin value of 60.55%, LEGN is doing good in the industry, outperforming 78.48% of the companies in the same industry.
- LEGN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 60.55% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- LEGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, LEGN has more shares outstanding
- Compared to 5 years ago, LEGN has more shares outstanding
- LEGN has a worse debt/assets ratio than last year.
2.2 Solvency
- An Altman-Z score of 5.23 indicates that LEGN is not in any danger for bankruptcy at the moment.
- Looking at the Altman-Z score, with a value of 5.23, LEGN is in the better half of the industry, outperforming 73.52% of the companies in the same industry.
- A Debt/Equity ratio of 0.26 indicates that LEGN is not too dependend on debt financing.
- With a Debt to Equity ratio value of 0.26, LEGN is not doing good in the industry: 66.67% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 5.23 |
ROIC/WACCN/A
WACC8.36%
2.3 Liquidity
- LEGN has a Current Ratio of 2.86. This indicates that LEGN is financially healthy and has no problem in meeting its short term obligations.
- LEGN has a Current ratio of 2.86. This is in the lower half of the industry: LEGN underperforms 65.71% of its industry peers.
- A Quick Ratio of 2.80 indicates that LEGN has no problem at all paying its short term obligations.
- LEGN's Quick ratio of 2.80 is on the low side compared to the rest of the industry. LEGN is outperformed by 64.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.86 | ||
| Quick Ratio | 2.8 |
3. Growth
3.1 Past
- LEGN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 32.11%, which is quite impressive.
- The Revenue has grown by 74.74% in the past year. This is a very strong growth!
- The Revenue has been growing by 59.90% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)32.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%67.65%
Revenue 1Y (TTM)74.74%
Revenue growth 3Y108.91%
Revenue growth 5Y59.9%
Sales Q2Q%69.99%
3.2 Future
- The Earnings Per Share is expected to grow by 32.56% on average over the next years. This is a very strong growth
- Based on estimates for the next years, LEGN will show a very strong growth in Revenue. The Revenue will grow by 36.44% on average per year.
EPS Next Y-1.27%
EPS Next 2Y56.87%
EPS Next 3Y51.61%
EPS Next 5Y32.56%
Revenue Next Year67.07%
Revenue Next 2Y57.13%
Revenue Next 3Y48.91%
Revenue Next 5Y36.44%
3.3 Evolution
- The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
- LEGN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- With a Price/Forward Earnings ratio of 48.07, LEGN can be considered very expensive at the moment.
- LEGN's Price/Forward Earnings ratio is rather cheap when compared to the industry. LEGN is cheaper than 89.90% of the companies in the same industry.
- Compared to an average S&P500 Price/Forward Earnings ratio of 23.94, LEGN is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 48.07 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- LEGN's earnings are expected to grow with 51.61% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y56.87%
EPS Next 3Y51.61%
5. Dividend
5.1 Amount
- LEGN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:LEGN (1/21/2026, 10:44:00 AM)
21.04
-2.38 (-10.16%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2025-11-12/bmo
Earnings (Next)03-09 2026-03-09/amc
Inst Owners47.87%
Inst Owner Change0.36%
Ins Owners0.08%
Ins Owner ChangeN/A
Market Cap3.86B
Revenue(TTM)908.96M
Net Income(TTM)-239.99M
Analysts83.33
Price Target72.06 (242.49%)
Short Float %19.63%
Short Ratio7.95
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-260.82%
Min EPS beat(2)-366.2%
Max EPS beat(2)-155.43%
EPS beat(4)1
Avg EPS beat(4)-127.99%
Min EPS beat(4)-366.2%
Max EPS beat(4)147.06%
EPS beat(8)2
Avg EPS beat(8)-64.68%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)3.59%
Min Revenue beat(2)-2.02%
Max Revenue beat(2)9.2%
Revenue beat(4)2
Avg Revenue beat(4)2.04%
Min Revenue beat(4)-2.02%
Max Revenue beat(4)9.2%
Revenue beat(8)4
Avg Revenue beat(8)1.55%
Revenue beat(12)6
Avg Revenue beat(12)20.38%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.86%
PT rev (3m)-5.79%
EPS NQ rev (1m)42.25%
EPS NQ rev (3m)45.92%
EPS NY rev (1m)-0.87%
EPS NY rev (3m)27.56%
Revenue NQ rev (1m)-1.49%
Revenue NQ rev (3m)-3.61%
Revenue NY rev (1m)-0.38%
Revenue NY rev (3m)-1.22%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 48.07 | ||
| P/S | 4.25 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 3.82 | ||
| P/tB | 3.82 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.29
EYN/A
EPS(NY)0.44
Fwd EY2.08%
FCF(TTM)-1.03
FCFYN/A
OCF(TTM)-0.93
OCFYN/A
SpS4.95
BVpS5.51
TBVpS5.51
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -14.01% | ||
| ROE | -23.73% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 60.55% | ||
| FCFM | N/A |
ROA(3y)-24.06%
ROA(5y)-29.02%
ROE(3y)-39.46%
ROE(5y)-43.13%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.53
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 78.25% | ||
| Cap/Sales | 2.01% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.86 | ||
| Quick Ratio | 2.8 | ||
| Altman-Z | 5.23 |
F-Score4
WACC8.36%
ROIC/WACCN/A
Cap/Depr(3y)97.56%
Cap/Depr(5y)226.91%
Cap/Sales(3y)9.76%
Cap/Sales(5y)32.83%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)32.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%67.65%
EPS Next Y-1.27%
EPS Next 2Y56.87%
EPS Next 3Y51.61%
EPS Next 5Y32.56%
Revenue 1Y (TTM)74.74%
Revenue growth 3Y108.91%
Revenue growth 5Y59.9%
Sales Q2Q%69.99%
Revenue Next Year67.07%
Revenue Next 2Y57.13%
Revenue Next 3Y48.91%
Revenue Next 5Y36.44%
EBIT growth 1Y45.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year53.06%
EBIT Next 3Y57.57%
EBIT Next 5Y36.08%
FCF growth 1Y61.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y63.38%
OCF growth 3YN/A
OCF growth 5YN/A
LEGEND BIOTECH CORP-ADR / LEGN FAQ
What is the ChartMill fundamental rating of LEGEND BIOTECH CORP-ADR (LEGN) stock?
ChartMill assigns a fundamental rating of 4 / 10 to LEGN.
Can you provide the valuation status for LEGEND BIOTECH CORP-ADR?
ChartMill assigns a valuation rating of 2 / 10 to LEGEND BIOTECH CORP-ADR (LEGN). This can be considered as Overvalued.
Can you provide the profitability details for LEGEND BIOTECH CORP-ADR?
LEGEND BIOTECH CORP-ADR (LEGN) has a profitability rating of 2 / 10.
What is the financial health of LEGEND BIOTECH CORP-ADR (LEGN) stock?
The financial health rating of LEGEND BIOTECH CORP-ADR (LEGN) is 4 / 10.